CytoMed Therapeutics Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, today announced that it has entered into a Research Collaboration Agreement ("RCA") with Sengkang General Hospital Pte Ltd ("SKH"), a public hospital in Singapore and a member of the SingHealth group to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells ("UC-MSCs") to treat cartilage injury. This injectable therapy will be implemented in vivo to support the application and commencement of a proposed Phase 1 clinical trial in Singapore, and is anticipated to complete within two years.